SavedAdd your journal

Journals / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2019 / Cilt: 32 - Sayı: 4

The good face of Cannabis sativa: cannabidiol

Cüneyt EVREN
Gökhan UMUT
Pages
283–288
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this Editorial, the characteristics of CBD and its place in various psychiatric disorders will be briefly discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cannabidiol (CBD) is the second-most common phytocannabinoid found in cannabis plants after tetrahydrocannabinol (THC).
📊
Key Findings & Data:Unlike THC, no psychoactive effect has been demonstrated for CBD.
💡
Conclusion & Impact:In this Editorial, the characteristics of CBD and its place in various psychiatric disorders will be briefly discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Cannabidiol (CBD) is the second-most common phytocannabinoid found in cannabis plants after tetrahydrocannabinol (THC). Unlike THC, no psychoactive effect has been demonstrated for CBD. Due to its effect on various neurotransmitter systems, it has been tried for the treatment of many physical and psychiatric diseases, considering its neuroprotective and anti-inflammatory properties. In this Editorial, the characteristics of CBD and its place in various psychiatric disorders will be briefly discussed.

🔖

Cite This Article

EVREN, C., UMUT, G. (2019). The good face of Cannabis sativa: cannabidiol. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 32 - Sayı: 4, 283–288. https://ajindex.com/articles/217737

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Chye Y, Christensen E, Solowij N, Yucel M. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry 2019; 10:63
  2. WHO (World Health Organization). Cannabidiol (CBD). 39th ECDD (Expert Committee on Drug Dependence) Agenda item 5.2. Geneva, 2017. https://www.who.int/medicines/access/ controlled-substances/5.2_CBD.pdf. Accessed [October 2019] 3. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 2017; 175:133-150
  3. Prud’homme M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse 2015; 9:33-38
  4. White CM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol 2019; 59:923-934
  5. Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, Walsh SL. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 2017; 172:9-13
  6. Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav 2018; 88:162-71
  7. Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, MacKillop J. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res 2019; 43:550-563
  8. Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Hasko G, Mechoulam R, Gao B, Pacher P. Cannabidiol attenuates alcoholinduced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep 2017; 7:12064
  9. Viudez-Martinez A, Garcia-Gutierrez MS, Navarron CM, Morales-Calero MI, Navarrete F, Torres-Suarez AI, Manzanares J. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol 2018; 23:154-164
  10. Viudez-Martinez A, Garcia-Gutierrez MS, Fraguas-Sanchez AI, Torres-Suarez AI, Manzanares J. Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Br J Pharmacol 2018; 175:3369-3378
  11. Sabioni P, Le Foll B. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. F1000Res 2018; 7:173
  12. Garcia-Gutierrez MS, Navarrete F, Viudez-Martinez A, Gasparyan